RXRX Q2 2023 Earnings — Recursion Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RXRXRecursion Pharmaceuticals, Inc.

$2B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M+43.9% YoY

Gross Profit

$2M14.8% margin

Operating Income

-$82M-741.8% margin

Net Income

-$77M-696.5% margin

EPS (Diluted)

$-0.38

QoQ Revenue Growth

-9.2%

Cash Flow

Operating Cash Flow

-$67M

Free Cash Flow

-$71M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$667M

Total Liabilities

$198M

Stockholders' Equity

$469M

Cash & Equivalents

$406M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$8M	+43.9%
Gross Profit	$2M	-$7M	+124.9%
Operating Income	-$82M	-$66M	-23.5%
Net Income	-$77M	-$66M	-17.0%

Revenue Segments

License and Service

$11M100%

Grant

$1,0000%